Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: big changes at Biogen; Paxlovid still a work in progress; Farxiga goes stellar; Moderna hints at M&A; and a chat with Roche Pharma India’s CEO on rare diseases.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 May 2022, including: big changes at Biogen, Inc.; Paxlovid still a work in progress; Farxiga goes stellar; Moderna, Inc. hints at M&A; and a chat with Roche Holding AG Pharma India’s CEO on rare diseases.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus" - Scrip, 3 May, 2022.)

(Also see "Pfizer On Paxlovid: "There's Still A Long Way To Go"" - Scrip, 3 May, 2022.)

(Also see "AstraZeneca’s Farxiga Flies Across $1bn Barrier" - Scrip, 29 Apr, 2022.)

(Also see "Moderna Teases M&A Interest As Pandemic Expected To Wind Down" - Scrip, 4 May, 2022.)

(Also see "It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support" - Scrip, 2 May, 2022.)

 

 
 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel